Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23551779 | 0.80 | CRBN (0.49) | CRBNDDB1 | |
| SCHEMBL23551677 | 0.80 | CRBN (0.49) | CRBNDDB1 | |
| SCHEMBL24753401 | 0.80 | CRBN (0.49) | CRBNDDB1 | |
| SCHEMBL22144655 | 0.76 | RAB9A (0.47) | GAATSHRCRBNDDB1ALDH1A1 | |
| SCHEMBL12316475 | 0.76 | — | — | |
| SCHEMBL15864812 | 0.75 | MAP3K14 (0.48) | GAATSHRMAP3K14CRBNDDB1 | |
| SCHEMBL25091484 | 0.74 | CRBN (0.46) | MAP3K14CRBNTOP2ATOP2BALDH1A1 | |
| SCHEMBL21843866 | 0.72 | ALDH1A1 (0.49) | TSHRALDH1A1 | |
| SCHEMBL22106713 | 0.71 | — | — | |
| SCHEMBL473720 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070196360-A1 | SUCCINIMIDE AND MALEIMIDE DERIVATIVES AND THEIR USE AS TOPOISOMERASE II CATALYTIC INHIBITORS | TOPOTARGET A/S | 2007-08-23 | — | — | US | disclosed |
| EP-1373494-B1 | SUCCINIMIDE AND MALEIMIDE DERIVATIVES AND THEIR USE AS TOPOISOMERASE II CATALYTIC INHIBITORS | TOPOTARGET AS (DK) | 2006-03-01 | — | — | EP | disclosed |
| US-20030032625-A1 | Succinimide and maleimide derivatives and their use as topoisomerase II catalytic inhibitors | TOPO TARGET APS (DK) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032625-A1 | Succinimide and maleimide derivatives and their use as topoisomerase II catalytic inhibitors | TOP2A, TOP2B, TOP1 | GAA 976/4885TSHR 4828/4885MAP3K14 3276/4885 |
| US-20070196360-A1 | SUCCINIMIDE AND MALEIMIDE DERIVATIVES AND THEIR USE AS TOPOISOMERASE II CATALYTIC INHIBITORS | TOP2A, TOP2B, TOP1 | GAA 976/4885TSHR 4828/4885MAP3K14 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.